Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

INTRODUCTION: Enzyme replacement therapy (ERT) with alpha-Galactosidase A (aGal A) may cause antibody (AB) formation against aGal A in males with Fabry disease (FD). Anti agalsidase ABs negatively influence globotriaosylceramide (Gb3) reduction. We investigated the impact of agalsidase AB on Gb3 and...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Rombach, Saskia M., Aerts, Johannes M. F. G., Poorthuis, Ben J. H. M., Groener, Johanna E. M., Donker-Koopman, Wilma, Hendriks, Erik, Mirzaian, Mina, Kuiper, Sijmen, Wijburg, Frits A., Hollak, Carla E. M., Linthorst, Gabor E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Public Library of Science 2012
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC3477102/
https://ncbi.nlm.nih.gov/pubmed/23094092
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0047805
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak